Search Bar & Filters
Found 25 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety, tolerability, pharmacokinetics, immune response, and early clinical effects of BNT3212, both alone and combined with pumitamig, in adults with advanced solid tumors who have exhausted other treatment options. This first-in-human, open-label study includes dose escalation and expansion phases to find the best dose and assess how the treatments work across different tumor types. The study is divided into four parts Part A and Part B focus on BNT3212 as a single therapy, with dose escalation followed by dose expansion in specific tumor types. Parts C and D evaluate the combination of BNT3212 with a fixed dose of pumitamig, again starting with dose escalation and then expansion cohorts. Treatments are given by intravenous infusion, and doses are adjusted to find the maximum tolerated dose and recommended dose for further study. Participants will undergo regular monitoring including safety assessments, blood tests to study drug levels and immune reactions, and imaging to measure tumor response. Researchers will track side effects, treatment interruptions, and response rates over approximately 31 months. The study also measures progression-free and overall survival. Continuous evaluation of safety and clinical data supports participant well-being throughout the trial.
Actively Recruiting
Researchers are investigating PRO-203, a drug administered under the skin, in a two-part study involving healthy adults and people with Systemic Sclerosis SSc. The goal is to understand the safety, tolerability, and how the drug behaves in the body at increasing dose levels. The study is phase 12, randomized, double-blind, and placebo-controlled in healthy volunteers, followed by an open-label phase in participants with SSc. In Part 1, healthy volunteers received a single subcutaneous dose of PRO-203 or a matching placebo across three dose groups. Enrollment for Part 1 is complete. Part 2 involves up to 24 participants with SSc who receive a single cycle of PRO-203 in multiple cohorts, with an optional long-term extension where eligible participants may receive retreatment if criteria are met. Each participants total study duration may last up to 53 weeks. Participants undergo regular assessments including safety monitoring through adverse event tracking and laboratory tests over 13 weeks for healthy volunteers and 49 weeks for SSc participants. Researchers also measure pharmacokinetics, pharmacodynamics, and immunogenicity of PRO-203. The study includes physical exams, ECGs, and blood tests, with dosing and follow-up visits scheduled throughout the study periods to monitor effects and safety.
Actively Recruiting
Researchers are conducting a randomized controlled trial to evaluate the safety and effectiveness of a modified acupotomy technique guided by ultrasound in treating ankylosing spondylitis AS. The study aims to clarify how this modified acupotomy impacts disease activity in patients, improve clinical outcomes, and provide evidence-based support for acupotomy as a treatment for AS. This trial also seeks to enhance diagnosis and treatment standards for this condition. Participants will be assigned to one of two groups. The experimental group will receive ultrasound-guided acupotomy once a week for four weeks. This involves identifying target vertebral and treatment sites using physical exams and ultrasound, followed by needle insertion under real-time ultrasound to release tissue at specific spinal areas. The comparator group will receive a sham procedure that mimics the preparation and needle insertion but only penetrates superficially without tissue release. Both groups undergo four treatment sessions in total. During the study, participants will be assessed at baseline and at weeks 2, 4, and 8 using multiple measures such as the Bath Ankylosing Spondylitis Disease Activity Index BASDAI, Ankylosing Spondylitis Disease Activity Score, functional and metrology indices, quality of life scores, and pain scales. Safety is monitored by recording adverse events throughout the study. The primary outcome is the change in BASDAI score one week after the final treatment session, with a total participation timeline extending to eight weeks for follow-up evaluations.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of pCAR-19B, an anti-CD19 CAR-T cell therapy, for children and adolescents aged 3 to 21 years with CD19-positive relapsed or refractory B-cell acute lymphoblastic leukemia. This phase II, multi-center, single-arm, open-label study focuses on patients whose leukemia has not responded to prior treatments or has relapsed. The study aims to assess the response rate and other outcomes after treatment with the investigational therapy. Participants will first have their lymphocytes collected through leukapheresis. After the collected cells are prepared into pCAR-19B cells, patients will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine for three consecutive days. This is followed by an intravenous infusion of the pCAR-19B cells at a targeted dose. The treatment period includes careful administration and monitoring of this cell infusion. Throughout the study, participants will undergo assessments including bone marrow evaluations, blood tests, and monitoring for adverse effects and response to treatment. Researchers will measure outcomes such as objective response rate at three months, minimal residual disease, overall survival, duration of response, relapse-free survival, and event-free survival over two years. Safety data and pharmacokinetic and pharmacodynamic parameters will also be collected. The study is planned to complete by mid-2029.
Actively Recruiting
Researchers are evaluating CNSI-Fe, an innovative anti-cancer drug containing Fe2 loaded on carbon nanoparticles, in people with advanced solid tumors. CNSI-Fe works by regulating a cell death process called ferroptosis and aims to improve cancer treatment through intratumoral injections. This Phase IbIIa study follows an initial Phase I trial where different doses showed promising safety and disease control in various advanced solid tumor patients. Participants will receive CNSI-Fe injections directly into 1 to 3 tumor lesions every two weeks for a total of 4 doses, with the possibility of additional doses if the benefits outweigh risks. The study includes a screening period, treatment period, and follow-up phase. Tumor response and safety will be closely monitored, and injections will stop or switch lesions based on tumor shrinkage or disappearance. During the study, participants will undergo safety checks before each dose and tumor evaluations at specified intervals, including before the third dose, after the fourth dose, and every six weeks thereafter. Follow-up includes safety monitoring 28 days after the last dose and regular checks for disease progression until new treatment, death, or study end. Samples will be collected at scheduled visits to assess safety, drug levels, and anti-tumor effects.
Actively Recruiting
Researchers are conducting a multicenter, ambispective cohort study to collect and analyze samples and data from patients with acute ischemic stroke caused by large vessel occlusion AIS-LVO. The study aims to build a comprehensive biobank including thrombi, intracranial blood, peripheral arterial and venous blood, along with clinical, laboratory, imaging, and follow-up information. This will help explore differences in blood samples and develop a detailed multiomics profile related to stroke. Samples such as blood clots and blood from different sites undergo pathological, metabolomic, proteomic, and genomic tests for multidimensional analysis. The study collects data from five stroke centers and includes pathological and histological examination of thrombus samples for some patients. Researchers plan to use these findings to identify stroke causes, therapeutic targets, risk factors, and prognosis by creating prediction models based on the combined multiomics data. Participants provide clinical and biological samples, and their health status is monitored through clinical and imaging evaluations over time. The primary outcome measured is the number of patients experiencing futile recanalization from enrollment to three months follow-up. Secondary outcomes include stroke causes, hemorrhagic transformation within seven days, and infarct expansion at baseline. The study is observational and involves no experimental treatments, focusing on data and sample collection to advance stroke research.
Actively Recruiting
Psoriasis is a chronic, recurring inflammatory disease influenced by genetics and environmental factors, marked by skin lesions that can affect multiple organs. Researchers are evaluating the effectiveness of different treatments chosen by patients in real-world clinical settings, comparing phototherapy, traditional systemic therapies, and biologics among Chinese psoriasis patients. This observational study aims to gather real-world evidence under routine care without intervention. Patients diagnosed with psoriasis by dermatologists choose their preferred treatments, which may include phototherapy, traditional systemic drugs, or biologics. The study does not assign treatments but observes outcomes as patients follow their chosen therapies. Data collection is supported through a phone application called Psoriasis New World, and the study includes multiple centers. Participants will be assessed regularly for treatment effectiveness using measures such as the Psoriasis Area and Severity Index PASI, Physician and Investigator Global Assessments, Body Surface Area affected, and Dermatology Life Quality Index. Adverse events and laboratory tests, including liver function, will be monitored throughout up to 12 months. The primary outcome is the percentage of patients achieving complete skin clearance PASI 100 at 6 months, with additional follow-up evaluations at 12 months.
Actively Recruiting
Researchers are evaluating the efficacy and safety of BR005-036C tablets compared to placebo in adults experiencing acute migraine attacks, including those with or without aura. This phase IIIII, multicenter, randomized, double-blind study aims to better understand how well BR005-036C works to relieve migraine symptoms and how it compares to placebo treatment. Participants are randomly assigned to take one of two doses of BR005-036C oral tablets or a matching placebo tablet. The study assesses the medications effects shortly after dosing, focusing on relief from pain and bothersome symptoms within two hours. The trial includes a treatment period with close monitoring for up to nine days after taking the study drug. During the study, participants will be monitored for migraine pain relief, freedom from symptoms, use of rescue medications, and functional ability after dosing. Researchers will track adverse events and other safety measures throughout the treatment period. The primary outcomes focus on pain freedom and symptom relief two hours after dosing, with additional assessments up to 48 hours. Participants involvement includes medication dosing and follow-up visits to assess their response and safety.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of two different treatment regimens to eradicate Helicobacter pylori infection. This trial compares a dual therapy using linralase glutarate capsules combined with amoxicillin against a quadruple therapy that includes bismuth. The main goal is to see if the dual therapy is not less effective than the quadruple therapy, while also monitoring patient adherence and side effects. This is a phase 4, randomized, open-label study aimed at first-line treatment of this infection. Participants receive either the dual-drug regimen of linralase glutarate capsules 50 mg twice daily plus amoxicillin 1 g three times daily or the quadruple therapy consisting of esomeprazole 20 mg twice daily, clarithromycin 0.5 g twice daily, amoxicillin 1 g twice daily, and colloidal bismuth subcitrate 200 mg twice daily. Both treatment courses last for 14 days. The study groups are assigned randomly and monitored during and after treatment to assess outcomes. During the study, participants undergo testing to determine the Helicobacter pylori eradication rate 28 days after treatment ends. Researchers also track adverse events during the 14 days of treatment and for 28 days following treatment completion. Participants adherence to the medication regimens is evaluated throughout. The trial includes adults aged 18 to 70 years who meet specific diagnostic and health criteria. The total duration from treatment to outcome measurement spans about 6 weeks, including follow-up assessments.
Actively Recruiting
The trial focuses on hospitalized children aged 0 to 18 years who require gastric tube placement, aiming to improve practices in pediatric enteral nutrition. Researchers are evaluating evidence-based methods to enhance safety and effectiveness in tube placement by addressing gaps between current practices and the latest guidelines. This quality improvement project seeks to update healthcare professionals knowledge and standardize procedures to improve pediatric care quality. The study involves establishing an enteral nutrition management team that will lead a 3-month quality improvement initiative. During this time, pediatric nurses will receive regular training through lectures, group discussions, demonstrations, and simulations focused on gastric tube placement and maintenance. The project will observe changes in compliance with protocols and nursing knowledge as the new practices are implemented. Participants will be monitored through assessments of protocol adherence and knowledge levels before and after the intervention. Data collected will include compliance rates with gastric tube placement protocols and the personal knowledge of nursing staff. The study aims to ensure safer and more effective tube placement, with evaluations conducted throughout the 3-month implementation period and ongoing support for nurses.
1-10 of 25
1